


Complications of chronic **IRON OVERLOAD** from blood transfusions



Chronic iron overload is a condition that develops when the body's limited iron storage capacities are exceeded¹. Since there is no natural way to remove excess iron from the body, iron builds up and can result in organ damage and other severe health complications¹.

The major cause of chronic iron overload is regular blood transfusions, which can be required for managing health conditions such as sickle cell disease, thalassemia, and myelodysplastic syndromes². Complications from chronic iron overload may vary with each disease.

Importance of Iron Chelation Therapy

Chelation is the recommended treatment for removing excess iron in patients with transfusional chronic iron overload¹¹. Patients should work with their doctors to monitor iron levels as part of their overall treatment plan, learning about the risks associated with iron toxicity and the importance of using iron chelation therapy.

REFERENCES:

- Shander A, Cappellini MD, Goodnough LT. Iron overload and toxicity: the hidden risk of multiple blood transfusions. *Vox Sanguinis*. 2009; 97: 185-197.
- Kohgo Y, Ikuta K, Ohtake T, et al. Body iron metabolism and pathophysiology of iron overload. *Int J Hematol*. 2008 Jul; 88(1): 7-15.
- Olivieri NF. Progression of Iron Overload in Sickle Cell Disease. *Semin Hematol*. 2001;38;(1 Suppl 1): 57-62.
- Ballas SK. Iron overload is a determinant of morbidity and mortality in adult patients with sickle cell disease. *Semin Hematol*. 2001;38(1 suppl 1):30-36.
- Adamkiewicz TV. Serum ferritin level changes in children with sickle cell disease on chronic blood transfusion are nonlinear and are associated with iron load and liver injury. *Blood*. 2009;114(21): 4632-4638.
- Chulamokha L, Scholand SJ, Riggio JM, et al. Bloodstream infections in hospitalized adults with sickle cell disease: a retrospective analysis. *Am J Hematol*. 2006;81(10):723-728.
- List AF. Iron Overload in Myelodysplastic Syndromes: Diagnosis and Management. *Cancer Control*. 2010; 17(1): 2-8.
- Pullarkat V. Objectives of iron chelation therapy in myelodysplastic syndromes: more than meets the eye? *Blood*. 2009. 114: 5251-5255.
- Borgna-Pignatti C, Gamberini MR. *Expert Rev Hematol*. 2011. 4(3):353-366.
- Cappellini M-D, Cohen A, Eleftheriou A, Piga A, Porter J, Taher A, eds. *Guidelines for the Clinical Management of Thalassemia*. 2nd rev ed. Nicosia, Cyprus: Thalassemia International Federation; 2008.
- Andrews NC. Disorders of iron metabolism. *New England Journal of Medicine*. 1999; 341:1986-1995.